In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pulmocide Ltd.

www.pulmocide.com

Latest From Pulmocide Ltd.

RSV Market: An Unmet Clinical Need For ReViral, And Big Pharma Too

The market landscape for drugs against respiratory syncytial virus infections, an important risk factor in premature infants and the immunocompromised, may change drastically in the future with numerous potential therapies in the pipeline.

Clinical Trials Research & Development

Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO

La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.

Commercial Companies

Inhaled Anti-Infectives With Extended Lung Retention: Pulmocide Secures Cash To Fund Trials

When tackling pulmonary infections, getting therapeutics into the lungs that stay there long enough to be effective is the key challenge. Pulmocide has just persuaded investors it is up to the task, raising $30m to fund two clinical programs.

Commercial Companies

F-Prime Plays The Long Game In Health Care Investing

With strong backing, F-Prime Capital Partners can make large, high-risk bets around the world — and keep doubling down. An interview with F-Prime Managing Partner Stephen Knight.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Pulmocide Ltd.
  • Senior Management
  • Garth Rapeport, MD, PhD, CEO
    Pete Strong, PhD, CSO
  • Contact Info
  • Pulmocide Ltd.
    Phone: 207 594 1210
    Level 1 Bessemer Bldg. (RSM)
    Prince Consort
    London, SW7 2BP
    UK
UsernamePublicRestriction

Register